Inoussa Ilboudo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Mr. Inoussa Ilboudo | Stem Cell Research | Best Researcher Award

Nazi Boni University | Burkina Faso

Dr. Inoussa Ilboudo is an expert in food safety and post-harvest management of plant production, currently pursuing a doctoral thesis at Nazi Boni University (UNB) with a focus on food safety. He holds a master’s degree in post-harvest management of plant production from Joseph Ki-Zerbo University (UJKZ) and a license in applied human nutrition from IST. His professional experience spans food quality control, contaminant analysis, and agricultural product safety. Dr. Ilboudo has received specialized training in food contaminant analysis with Laval University (Canada), mycotoxin quantification using LC-MS/MS in Morocco, heavy metal analysis by atomic absorption spectrometry, GC-MS application in Pretoria, and chromatographic methods at the University of Helsinki. As Head of the Contaminants and Food Additives Department, he has led initiatives such as the implementation of peanut standards for infant flours and contributed to national food safety projects like ReCMA-BF. A member of the American Chemical Society, Dr. Ilboudo is also a certified master trainer under the GIZ/MOVE program and teaches quality control of fruits and vegetables in academic institutions. His research interests center on the assessment of food contaminants, post-harvest loss reduction, and the development of safer food systems in West Africa.

Profile: Orcid

Featured Publications:

Ilboudo, I., Compaoré, H., Compaoré, I., Traoré, S. M., Dembélé, L. E., Nikièma, F., Lanterbecq, D., Sawadogo‐Lingani, H., & Kabré, E. (2025). Biocontrol of aflatoxigenic maize molds using Lactobacillus spp.-based formulations. Food Science & Nutrition. Advance online publication.

 

Kelly Bosak | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Kelly Bosak | Stem Cell Research | Best Researcher Award

University of Kansas Medical Center | United States

Dr. Kelly A. Bosak, PhD, APRN, ANP-BC, FHFSA, is a tenured Associate Professor at the University of Kansas Medical Center and a nationally recognized expert in heart failure care, nursing science, and implementation research. With a strong background in advanced practice nursing and nursing administration, Dr. Bosak has made significant contributions to interdisciplinary research focused on improving clinical outcomes in cardiology, rural health, and chronic disease management. Her peer-reviewed work spans high-impact journals such as The Journal of Cardiac Failure, Implementation Science, and The Journal for Nurse Practitioners, reflecting her leadership in both clinical practice and academic scholarship. Dr. Bosak has authored or co-authored over 30 peer-reviewed publications, with a Scopus h-index of 10, over 450 citations, and 32 documents indexed in major databases. She has played a pivotal role in national reports from the Heart Failure Society of America and led multiple implementation science projects aimed at integrating evidence-based interventions into routine care. Her current research emphasizes digital health innovation and workforce development in underserved communities. Dr. Bosak’s interdisciplinary collaborations and translational research continue to shape evidence-based practice and policy in cardiovascular nursing and advanced practice nursing education.

Profiles: Google Scholar | Scopus

Featured Publications:

  • “Return on Investment of a Nurse Practitioner Fellowship Program”

  • “Interprofessional Education for Improving Workforce Capacity to Treat COPD and Long COVID in Rural Communities”

  • “Shared Decision Making for the Pulmonary Artery Monitoring Device for Patients with Heart Failure”

  • “Implementation of a SmartPhrase for Exercise in the Electronic Health Record for Individuals with Heart Failure”

  • “Implementing a Standardized Workflow for Early Detection of Steroid-Induced Hyperglycemia in Allogeneic Stem Cell Transplant Recipients: A Quality Improvement Project”

  • “Team Science”

  • “Ceramides as Novel Biomarkers of Cardiometabolic Conditions”

  • “Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America”

  • “Heart Failure Epidemiology and Outcomes Statistics, A Report of the Heart Failure Society of America”

  • “Implementation Mapping and Concept Mapping to Explore Guideline Implementation in the Heart Failure Clinic”

  • “Coordinating Resources for a Hybrid Effectiveness and Implementation Trial Across an Integrated Digital Network for Heart Failure”

  • “Creating a Standardized Approach to Program Evaluation in a Magnet Recognized Pediatric Hospital System”

 

 

 

Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Published on by Cell Biologist

Dr. Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Kfshrc | Saudi Arabia

Dr. Ali Alahmari is a distinguished consultant in Acute Leukemia, Hematology, Hematopoietic Stem Cell Transplantation (HSCT), and Cellular Therapy at King Faisal Specialist Hospital & Research Centre. He earned his MBBS degree from King Saud University and completed his internship at King Khalid University Hospital. He has held a key consultant position, contributing extensively to the advancement of cellular therapy and bone marrow transplantation in Saudi Arabia. Dr. Alahmari has made significant academic contributions to the field, particularly in hemato-hepatology and sickle cell disease. His research has focused on novel transplant approaches, including haploidentical stem cell transplantation after liver transplantation and donor impact in severe aplastic anemia. He has co-authored over 22 scientific documents, with his work accumulating more than 629 citations and earning an h-index of 12, reflecting the depth and influence of his research. His notable publications include titles such as “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia“ and “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction.” Dr. Alahmari’s ongoing efforts continue to shape clinical best practices and research frameworks for hematologic disorders and transplantation medicine in the region.

Profile: Scopus

Featured Publications:

  • “Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT”

  • “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia”

  • “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease”

  • “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation”

  • “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”

Francesco Gaudio | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Francesco Gaudio | Stem Cell Research | Best Researcher Award

Prof. Francesco Gaudio, LUM UNIVERSITY, Italy

Prof. Francesco Gaudio is a highly accomplished hematologist with over 20 years of clinical and academic expertise, specializing in lymphoproliferative neoplasms and hematopoietic stem cell transplantation. Currently serving as Assistant Professor in Hematology at University LUM Giuseppe Degennaro and a practicing medical doctor at “F. Miulli” Hospital, he has previously held long-term roles at renowned Italian hospitals. With a prolific research record, he has authored over 50 publications in high-impact journals and contributed more than 100 abstracts to international conferences. He has conducted research in leading global institutions, including Memorial Sloan-Kettering and Imperial College. Alongside clinical innovation, he is a passionate educator and experienced healthcare manager. His focus on therapeutic advances and multidisciplinary care makes him a leader in hematology research and oncology care.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical and Academic Experience
    Over 20 years of dedicated work in hematology, with expertise in lymphoproliferative disorders and hematopoietic stem cell transplantation.

  2. Robust Research Profile

    • More than 50 peer-reviewed publications in Impact Factor journals.

    • 100+ abstracts presented internationally.

    • Principal and co-investigator in multinational clinical studies.

  3. Global Exposure & Collaborations
    Research training and collaborations at globally recognized centers:

    • Memorial Sloan-Kettering (USA)

    • Imperial College (UK)

    • Lyon Sud (France)

    • VHIO Barcelona (Spain)

  4. Commitment to Academic Growth

    • Teaches Blood Diseases, Oncology, and Pathology.

    • Holds National Scientific Qualification for Associate Professor level.

  5. Leadership & Management Training

    • Managerial courses from SDA Bocconi, ISTUD Foundation, and CURSUS.

  6. Multidisciplinary Impact
    Engages in translational research that bridges hematology, oncology, and emerging areas like cannabinoid therapies and survivorship in cancer.

⚠️ Areas for Improvement:

  1. Leadership in High-Impact Authorship
    While his contribution as co-author is commendable, increasing first or senior authorship in landmark studies would strengthen his research leadership visibility.

  2. Grant Leadership and Funding Acknowledgment
    No mention of competitive grant acquisition or principal leadership in major funded research networks; pursuing this could enhance academic competitiveness.

  3. Public Engagement and Open Science
    Could further boost impact by increasing participation in open-access platforms, public talks, and wider media dissemination of research findings.

🎓 Education:

Prof. Gaudio holds a Degree in Medicine and Surgery from the University of Bari (1995–1996), where he explored clonogenic hematopoietic activity in lymphoma patients. He specialized in Hematology (2001–2002), focusing on stem cell mobilization challenges. He further expanded his scientific foundation with a Postgraduate Specialization in Chemico-Pharmaceutical Research from CARSO (1998). Recognized for academic excellence, he earned the National Scientific Qualification (ASN) for Associate Professor in Hematology, Oncology, and Rheumatology in 2020. His academic path is complemented by top-tier executive and managerial training, including healthcare leadership programs from SDA Bocconi, ISTUD Foundation, and CURSUS. Early education includes a Classical High School Diploma from Liceo Classico ‘Quinto Ennio’, Taranto. His diverse education underscores a balanced mastery of clinical medicine, research, and institutional leadership.

💼 Professional Experience:

Prof. Gaudio’s medical journey spans over two decades in hematology and oncology. Since April 2024, he serves as an Assistant Professor at University LUM Giuseppe Degennaro and practices medicine at “F. Miulli” Regional Hospital. Prior to this, he was a senior hematologist at Policlinico Consorziale, AOU Bari for nearly 19 years, providing expert care and engaging in impactful research. He also worked at Ospedali Riuniti in Foggia, honing his clinical foundations. His experience includes leadership in clinical trials, management of complex hematologic malignancies, and therapeutic protocol development. He is a sought-after speaker, educator, and research collaborator with exposure to international institutions including Sloan-Kettering (USA), Imperial College (UK), and VHIO (Spain). His long-standing service and global outreach reflect deep dedication to patient care, academic excellence, and translational medicine.

🔬 Research Focus:

Prof. Gaudio’s research focuses on lymphomas, leukemias, and hematopoietic stem cell transplantation, combining clinical acumen with molecular innovation. As Principal Investigator in numerous global trials, he has helped shape advanced therapeutic strategies and enhance survival in hematological malignancies. His work delves into mobilization of CD34+ stem cells, radiotherapy-induced toxicity, and biological markers of malignancy. Recent systematic reviews explore epithelial–mesenchymal transcription factors, BPDCN, and the neurological impact of cannabidiol. His interests also span survivorship in Hodgkin lymphoma patients, with emphasis on long-term toxicity and risk evaluation. His teaching integrates updated scientific evidence into medical curricula, training the next generation of hematologists. International collaborations and cross-border research highlight his commitment to innovation and best practices in oncology. Prof. Gaudio’s work not only advances hematology but also bridges clinical gaps through interdisciplinary solutions.

📚 Publications Top Notes:

📄 Exploring the Role of Epithelial–Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review 🔬🧬

📄 Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity 🎗️📊

📄 Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34+ cells in patients with relapsed-refractory diffuse large B-cell lymphomas 🩸💉

📄 The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review 🌿🧠

📄 Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview 🔎🧫

📝 Conclusion:

Prof. Francesco Gaudio is a highly qualified and deserving candidate for the Best Researcher Award. His two decades of contribution to hematology and oncology, combined with a prolific publication record, international collaboration, and dedication to clinical innovation, clearly demonstrate excellence in medical research. While opportunities exist for expanded authorship leadership and grant visibility, his current achievements are deeply impactful and relevant to modern hematologic science. His work bridges bench-to-bedside approaches and continues to benefit both the scientific community and patient outcomes.